Sotera Health Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Sotera Health wird ein jährliches Gewinn- und Umsatzwachstum von 29% bzw. 5.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 28.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 25.7% betragen.
Wichtige Informationen
29.0%
Wachstumsrate der Gewinne
28.22%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 5.7% |
| Zukünftige Eigenkapitalrendite | 25.75% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 18 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Analyseartikel • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...Narrativ-Update • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.Narrativ-Update • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).Narrativ-Update • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).Narrativ-Update • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).Narrativ-Update • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.Narrativ-Update • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.Seeking Alpha • Feb 20
Sotera Health: A Predictable And Growing Business
Summary Sotera Health's stock was volatile in 2025 but ultimately finished strong. The core business remains a stable franchise that has consistently grown sales and operating profits with zero down years in the last 20 years. 2025 marked an inflection year, with the core Sterigenics segment posting 10% revenue growth, up from ~4-7% in the previous two years. Read the full article on Seeking AlphaNarrativ-Update • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).Narrativ-Update • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
Neues Narrativ • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).Analyseartikel • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...Narrativ-Update • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.Narrativ-Update • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).Narrativ-Update • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.Analyseartikel • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...Analyseartikel • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...Narrativ-Update • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.Narrativ-Update • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.Narrativ-Update • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.Analyseartikel • Aug 13
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
Sotera Health Company ( NASDAQ:SHC ) shareholders would be excited to see that the share price has had a great month...Narrativ-Update • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.Analyseartikel • Jul 17
These 4 Measures Indicate That Sotera Health (NASDAQ:SHC) Is Using Debt Extensively
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 12
Is There An Opportunity With Sotera Health Company's (NASDAQ:SHC) 48% Undervaluation?
Key Insights Sotera Health's estimated fair value is US$23.38 based on 2 Stage Free Cash Flow to Equity Sotera Health's...Analyseartikel • May 13
Sotera Health Company's (NASDAQ:SHC) 28% Price Boost Is Out Of Tune With Revenues
Sotera Health Company ( NASDAQ:SHC ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Analyseartikel • Apr 24
What Does Sotera Health Company's (NASDAQ:SHC) Share Price Indicate?
Sotera Health Company ( NASDAQ:SHC ), might not be a large cap stock, but it saw a decent share price growth of 11% on...Analyseartikel • Mar 31
Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Mar 07
There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings
Sotera Health Company's ( NASDAQ:SHC ) earnings announcement last week didn't impress shareholders. Despite the soft...Analyseartikel • Feb 26
Some Confidence Is Lacking In Sotera Health Company's (NASDAQ:SHC) P/S
It's not a stretch to say that Sotera Health Company's ( NASDAQ:SHC ) price-to-sales (or "P/S") ratio of 3.5x right now...Analyseartikel • Jan 06
Why Sotera Health Company (NASDAQ:SHC) Could Be Worth Watching
While Sotera Health Company ( NASDAQ:SHC ) might not have the largest market cap around , it saw significant share...Analyseartikel • Dec 05
Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Neues Narrativ • Sep 02
Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth
Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.Analyseartikel • Sep 02
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable
With a median price-to-sales (or "P/S") ratio of close to 3.8x in the Life Sciences industry in the United States, you...Analyseartikel • Jun 25
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,395 | 290 | N/A | 467 | 5 |
| 12/31/2027 | 1,314 | 245 | 222 | 417 | 9 |
| 12/31/2026 | 1,241 | 201 | 120 | 326 | 9 |
| 3/31/2026 | 1,189 | 118 | 97 | 261 | N/A |
| 12/31/2025 | 1,164 | 78 | 149 | 287 | N/A |
| 9/30/2025 | 1,150 | 55 | 87 | 240 | N/A |
| 6/30/2025 | 1,125 | 24 | 113 | 266 | N/A |
| 3/31/2025 | 1,107 | 25 | 106 | 270 | N/A |
| 12/31/2024 | 1,100 | 44 | 45 | 224 | N/A |
| 9/30/2024 | 1,120 | 70 | 104 | 282 | N/A |
| 6/30/2024 | 1,098 | 40 | 32 | 226 | N/A |
| 3/31/2024 | 1,077 | 55 | -377 | -172 | N/A |
| 12/31/2023 | 1,049 | 51 | -363 | -148 | N/A |
| 9/30/2023 | 991 | -306 | -381 | -159 | N/A |
| 6/30/2023 | 976 | -268 | -342 | -133 | N/A |
| 3/31/2023 | 988 | -261 | 70 | 262 | N/A |
| 12/31/2022 | 1,004 | -234 | 96 | 278 | N/A |
| 9/30/2022 | 993 | 121 | 90 | 242 | N/A |
| 6/30/2022 | 971 | 123 | 127 | 256 | N/A |
| 3/31/2022 | 956 | 135 | 159 | 275 | N/A |
| 12/31/2021 | 931 | 115 | 179 | 282 | N/A |
| 9/30/2021 | 907 | 36 | 156 | 237 | N/A |
| 6/30/2021 | 881 | 9 | 127 | 202 | N/A |
| 3/31/2021 | 842 | -26 | 110 | 171 | N/A |
| 12/31/2020 | 818 | -39 | 67 | 121 | N/A |
| 9/30/2020 | 795 | -23 | 55 | 109 | N/A |
| 6/30/2020 | 790 | -28 | 68 | 124 | N/A |
| 3/31/2020 | 772 | -29 | 58 | 116 | N/A |
| 12/31/2019 | 778 | -21 | N/A | 149 | N/A |
| 12/31/2018 | 746 | -6 | N/A | 120 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SHCDas prognostizierte Gewinnwachstum (29% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: SHCDie Erträge des Unternehmens (29% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (18.9% pro Jahr).
Hohe Wachstumserträge: SHCEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: SHCDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13% pro Jahr).
Hohe Wachstumseinnahmen: SHCDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: SHCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (25.7%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/23 03:07 |
| Aktienkurs zum Tagesende | 2026/06/23 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Sotera Health Company wird von 13 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |